B-cell activity of polyclonal antithymocyte globulins

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Polyclonal antithymocyte globulins (AThG) are derived from immunized animal sera.
• AThG are utilized in treating antibody-mediated rejection in kidney transplant recipients.
• The thymic inoculum used for immunization contains B cells and plasma cells.

Purpose of the Study:

• To review experimental and clinical evidence of AThG's B-cell activity.
• To elucidate the mechanisms of action behind AThG's effects on B cells.
• To highlight the role of B-cell depletion in AThG therapy.

Main Methods:

• Review of existing literature on AThG.
• Analysis of in vivo and in vitro studies.
• Examination of B-cell markers (CD20, CD138) in relation to AThG activity.

Main Results:

• AThG induces apoptosis in naive, memory B cells, and plasma cells.
• B-cell reactive antibodies are present in AThG preparations.
• Successful in vivo treatment of antibody-mediated rejection is demonstrated.

Conclusions:

• AThG exhibits significant B-cell depleting activity.
• The B-cell activity of AThG contributes to its therapeutic efficacy in transplantation.
• Understanding these mechanisms can optimize AThG use in clinical practice.